PBYI logo

Puma Biotechnology (PBYI) Company Overview

Profile

Full Name:

Puma Biotechnology, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

April 24, 2012

Indexes:

Not included

Description:

Puma Biotechnology is a biopharmaceutical company focused on developing innovative cancer therapies. Its main product, Neratinib, is used to treat certain types of breast cancer. The company aims to improve treatment options and outcomes for patients with cancer through research and development of targeted therapies.

Events Calendar

Earnings

Next earnings date:

May 2, 2025

Recent quarterly earnings:

Feb 27, 2025

Recent annual earnings:

Feb 27, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 28, 25 HC Wainwright & Co.
Buy
Dec 23, 24 HC Wainwright & Co.
Buy
Nov 20, 24 HC Wainwright & Co.
Buy
Nov 8, 24 HC Wainwright & Co.
Buy
Aug 2, 24 HC Wainwright & Co.
Buy
Jul 26, 24 HC Wainwright & Co.
Buy
Jun 4, 24 HC Wainwright & Co.
Buy
Jun 3, 24 HC Wainwright & Co.
Buy
May 20, 24 HC Wainwright & Co.
Buy
May 3, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Puma Biotechnology?
  • Does Puma Biotechnology pay dividends?
  • What sector is Puma Biotechnology in?
  • What industry is Puma Biotechnology in?
  • What country is Puma Biotechnology based in?
  • When did Puma Biotechnology go public?
  • Is Puma Biotechnology in the S&P 500?
  • Is Puma Biotechnology in the NASDAQ 100?
  • Is Puma Biotechnology in the Dow Jones?
  • When was Puma Biotechnology's last earnings report?
  • When does Puma Biotechnology report earnings?
  • Should I buy Puma Biotechnology stock now?

What is the ticker symbol for Puma Biotechnology?

The ticker symbol for Puma Biotechnology is NASDAQ:PBYI

Does Puma Biotechnology pay dividends?

No, Puma Biotechnology does not pay dividends

What sector is Puma Biotechnology in?

Puma Biotechnology is in the Healthcare sector

What industry is Puma Biotechnology in?

Puma Biotechnology is in the Biotechnology industry

What country is Puma Biotechnology based in?

Puma Biotechnology is headquartered in United States

When did Puma Biotechnology go public?

Puma Biotechnology's initial public offering (IPO) was on April 24, 2012

Is Puma Biotechnology in the S&P 500?

No, Puma Biotechnology is not included in the S&P 500 index

Is Puma Biotechnology in the NASDAQ 100?

No, Puma Biotechnology is not included in the NASDAQ 100 index

Is Puma Biotechnology in the Dow Jones?

No, Puma Biotechnology is not included in the Dow Jones index

When was Puma Biotechnology's last earnings report?

Puma Biotechnology's most recent earnings report was on Feb 27, 2025

When does Puma Biotechnology report earnings?

The next expected earnings date for Puma Biotechnology is May 2, 2025

Should I buy Puma Biotechnology stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions